Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Cédric LukasJulia MaryMichel DebandtClaire DaïenJacques MorelAlain CantagrelBruno FautrelBernard CombePublished in: Arthritis research & therapy (2019)
ClinicalTrials.gov: NCT03666091. Registered September 11, 2018.